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Use of hormonal contraceptives has been associated with Staphylococcus aureus nasal
carriage in adult women. However, the role of hormonal contraceptives in S. aureus colo-
nization among adolescents and associations with progestin only contraceptives are
unknown.
Methods
We obtained nasal and throat swab samples from 439 girls aged 17–21 years in the popula-
tion-based Tromsø study Fit Futures, 2012–2013, Norway, with information on lifestyle,
health and biomarkers. We used multivariable logistic regression to study the association
between use of hormonal contraceptives and Staphylococcus aureus carriage while adjust-
ing for potential confounding factors.
Results
Staphylococcus aureus nasal carriage prevalence were 34%, 42%, and 61% among pro-
gestin-only users, non-users, and progestin-estrogen combination contraceptive users,
respectively (P<0.001). Use of combination contraceptives doubled the odds of nasal car-
riage (non-users reference; OR = 2.31, 95%CI = 1.43–3.74). The OR of nasal carriage was
0.29 among progestin-only users compared to combination contraceptives users (95% CI =
0.12–0.67).
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In this study, use of combination hormonal contraceptives was associated with higher risk of
Staphylococcus aureus nasal carriage in adolescent girls. Experimental design studies are
needed to establish the role of exogenous sex steroids in Staphylococcus aureus coloniza-
tion in women.
Introduction
Staphylococcus aureus colonizes the skin and mucosal surfaces including nose and throat, and
may cause a wide range of clinically important infections [1–3]. The nasal mucosa is the major
S. aureus reservoir associated with transmission to other body sites and auto-infections, as well
as transmission to others [1, 3–4]. The prevalence of nasal carriage increases from 20–30% in
young children to 40–50% in older children and adolescents, after which the prevalence drops
to 20–30% in the adult population [1, 3, 5–6]. Men have higher S. aureus nasal carrier rates
than women [7]. Exclusive throat carriage is increasingly identified as an additional S. aureus
reservoir particularly in young populations, but is considered less important in transmission
and infection [8–11].
Prevention and eradication of S. aureus carriage may reduce the S. aureus disease burden
[1, 3, 12]. In the carrier state, S. aureus is not successfully cleared by the host innate immune
system, which function is determined by genes and environment. No significant heritability of
S. aureus nasal carriage was found in a twin study [13], and evidence for host genetic determi-
nants from observational studies is scarce [14–18]. This motivates the search for modifiable
host lifestyle and environmental determinants as potential targets for prevention and infection
control [4]. The strong associations of S. aureus carriage with age and sex, suggest that repro-
ductive hormones may be key factors in regulating the immune response. Both endogenous
and exogenous sex steroid exposure have been associated with S. aureus nasal carriage in
women [19–21]. The initial hypothesis was partly based on in vitro evidence of increased
staphylococcal binding to HeLa cells in the presence of estrogen [22]. The first epidemiological
study showed an association between high circulating estrogen levels and staphylococcal nasal
carriage among women [21]. In a cohort study among 694 healthy female volunteers in their
third decade visiting a travel clinic, hormonal contraceptive (HC) users had an increased risk
(OR 1.6, 95% CI 1.1–2.3) of S. aureus carriage at baseline and an increased risk (OR 3.2, 95%
CI 1.4–7.3) of persistent S. aureus carriage after a median follow-up of 70 days, when com-
pared to non-users [19]. However, it was impossible to separate the effect of progestin and
estrogen as 96% used combination contraceptives. Another study based on nine HC users sup-
ports an association between oral hormonal contraceptives and nasal carriage [20]. Despite the
high prevalence of S. aureus nasal carriage among adolescents, the association with HC use in
women below 20 years has not been addressed.
In general, few host risk factors for S. aureus carriage have been investigated in adolescents,
besides the link with atopic dermatitis [23] and low vitamin D as a predictor of methicillin
resistant staphylococcus aureus (MRSA) nasal carriage [24]. Additional associations observed
among adults, include higher S. aureus nasal carriage rates with obesity and type 2 diabetes
[25], and lower rates in smokers [5].
The main aim of this study was to assess the association between overall use of HC and dif-
ferent types of HC, and S. aureus nasal and throat carriage in a population-based sample of
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healthy girls aged 17–21 years, and to test whether an association is independent of other
known risk factors for S. aureus carriage.
Methods
Population and study design
The Tromsø Study Fit Futures 1 and 2 (TFF1 and TFF2) comprise two waves of large popula-
tion-based studies of lifestyle and health among upper-secondary school students in the Norwe-
gian municipalities of Tromsø and Balsfjord [23, 26]. TFF2 was conducted in 2012–2013 and
invited all third year students (n = 775), as well as TFF1 participants not attending school in
2012–2013 (n = 464). A total of 31 individuals (27 participants in TFF1 and 4 new students)
could not be successfully contacted, and were not invited in TFF2. Among all students invited
to TFF2 (n = 1208), 868 participated (71.9%). All males, participants with no or invalid nasal or
throat swab, age exceeding 21 years, and females with missing data on HC use were excluded.
The final study population included 436 and 439 women for the analysis of S. aureus nasal and
throat carriage, respectively (Fig 1).
The participants had a half-day visit at The Clinical Research Unit, University Hospital of
North Norway (UNN). A web-based questionnaire was used to collect data on lifestyle, health
and disease. Nasal and throat swab cultures, clinical examinations, blood sampling, and inter-
views were performed by trained research nurses according to standardised procedures.
Height and weight were measured on an electronic scale with lightweight clothing, and body
mass index was calculated (kg/m2). Non-fasting blood samples were drawn from an antecubi-
tal vein. Methods for the assessment of EDTA-blood glycated hemoglobin (HbA1c) and serum
25-hydroxyvitamin D [25(OH)D] concentrations in TFF have been described previously [27].
Assessment of S. aureus carriage
Nasal and throat swab samples were collected by research nurses. A NaCl (0.9%)-moistened
sterile rayon-tipped swab rotated three times with a gentle pressure was used to sample both
vestibule nasi. A second swab was used to sample both tonsillar regions with moderate pres-
sure on the tonsillar surfaces. The swabs were immediately placed in transport medium
(Amies Copan, Brescia, Italy) and stored at 4˚C for 3–7 days (dx.doi.org/10.17504/protocols.
io.2j5gcq6). The microbiological analysis was done by trained personnel at the Department of
Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø.
First, the swabs were enriched in Bacto Staphylococcus medium broth (Difco laboratories,
Sparks, MD, USA) and incubated for 18–24 hours at 37 ˚C. After enrichment, one drop of
enrichment broth were streaked on blood agar (Oxoid, UK), CROMagar-plates for S. aureus
detection (SmithMed AS/Microbiological media production and MRSA agar plates SmithMed
AS/Microbiological media production, Department of Microbiology and Infection Control,
UNN). In a pilot study among 10 adult volunteers, we demonstrated the validity of the
method. One nasal swab sample from each nasal vestibule was taken and stored at 4˚C for 9
days before enrichment and plating, gave the same culturing result as beginning the culturing
with enrichment on the day of sampling. In order to increase statistical power and test for dif-
ferences between agar plates, each nasal swab was streaked on blood agar and two different S.
aureus growth media; the one used in the present study and chromId S. aureus agar (bioMér-
ieux, France). The agar plates were incubated for 42–48 hours at 37˚C. To retain high specific-
ity, colony morphology was examined and the most dominating colony type on the SAID or
MRSA plate was plated on blood agar and incubated for 20–24 hours at 37˚C before confirma-
tion as S. aureus by the Staphaurex plus agglutination test (Remel, USA). All confirmed S.
aureus isolates were frozen at– 70 ˚C in glycerol-containing liquid media for molecular
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Fig 1. The study population. The Tromsø Study, Fit Futures 2. �68 throat cultures with no bacterial growth were recoded as valid swabs negative for
S. aureus.
https://doi.org/10.1371/journal.pone.0218511.g001
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analysis (dx.doi.org/10.17504/protocols.io.2j6gcre). Growth of any bacterial colonies on any
of the agar plates was registered as a valid culture. S. aureus carriage state was determined by
nasal or throat swab positive for S. aureus. For throat cultures, all samples with no growth on
neither plate, were recoded as valid cultures negative for S. aureus (n = 68). One MRSA isolate
was confirmed from the nasal swabs. Two MRSA isolates from two different participants was
confirmed from throat swabs. The verification of MRSA was done by detection of the thermo-
stable nuclease of S. aureus and the mecA gene with the use of an in house real time PCR.
Assessment of hormonal contraceptive use
Self-reported information on current contraceptive use was obtained by trained nurses asking
female participants the interview questions: “If you have started menstruating; do you use any
kind of contraceptives?” (yes/no), and “If you use any kind of contraceptives; what type?”
(Tablets/Injections/Implants/Condom/Transdermal contraceptive patch/Vaginal contracep-
tive ring/Intrauterine device (IUD)/Other). Condom and other were defined as non-hormonal
contraceptives. None used IUD as contraception, and the variable was excluded from further
analysis.
HC users were asked about brand name of tablets, implants, transdermal contraceptive
patch, or vaginal contraceptive ring, and all were shown photos of different brands sold in
Norway to help correct reporting. In the analysis, HC types and brands were categorised
into combination HC and progestin-only HC. The combination HCs were further divided
into two groups according to the ethinylestradiol daily dosage (high and low). High dosage
was defined as HC containing� 30 μg ethinylestradiol. Low dosage was defined as contracep-
tives containing� 20 μg ethinylestradiol. No HC brand contained between 20 and 30 μg
ethinylestradiol.
Statistical analysis
Univariable associations and differences between comparison groups were analyzed in contin-
gency tables and by calculating means and standard deviations, using chi-square and t-tests to
quantify the potential role of chance. Univariable and multivariable logistic regression were fit-
ted to estimate odds ratios (ORs) and 95% confidence intervals (CIs) to describe the associa-
tion between HC use and S. aureus nasal and throat carriage while adjusting for potential
confounders. We used DAGitty 2.3 and Akaike Information Criterion (AIC) for model selec-
tion. Testing for potential interaction between explanatory variables was done by including the
multiplicative terms of two predictor variables in the model and comparing models using AIC.
We analyzed our data using SPSS version 23 and considered p-values < 0.05 as statistical evi-
dence and 0.1> p� 0.05 as weak statistical evidence.
Ethics
A declaration of consent was signed by each participant in TFF2. TFF2 was approved by the
Regional Committee for Medical and Health Research Ethics (REK) and the Norwegian Data
Protection Authority. The present study was approved by REK North, reference 2011/1710.
Results
In this population of healthy female adolescents with mean age 18 years (range 17–21), the
prevalence of S. aureus nasal carriage was 50.0% (218/436) while the prevalence of throat car-
riage was 49.7% (263/439). Simultaneous nasal and throat carriage were found in 178 partici-
pants. Table 1 shows selected population characteristics by S. aureus nasal and throat carriage
Hormonal contraceptive use and Staphylococcus aureus carriage
PLOS ONE | https://doi.org/10.1371/journal.pone.0218511 July 5, 2019 5 / 13
Table 1. Characteristics of the study population by S. aureus nasal and throat carriage. The Tromsø Study Fit Futures 2.









Pa OR (95% CI)b
Age, years (mean, SD) 18.2 (0.7) 18.3 (0.7) .37 1.13 (0.86–1.48) 18.3 (0.7) 18.3 (0.7) .65 0.86 (0.63–1.18)
BMI, kg/m2 (mean, SD) 23.2 (4.3) 23.1 (4.3) .74 0.99 (0.95–1.04) 23.3 (4.4) 23.0 (4.1) .53 0.97 (0.93–1.02)
BMI-category .66 .36
< 18.5 kg/m2 12 (57.1) 9 (42.9) 0.7 (0.29–1.70) 10 (47.6) 11 (52.4) 0.48 (0.19–1.24)
18.5-<25 kg/m2 154 (48.3) 165 (51.7) 1.0 (ref) 121 (37.6) 201 (62.4) 1.0 (ref)
25-<30 kg/m2 35 (55.6) 28 (44.4) 0.75 (0.43–1.29) 29 (46.0) 34 (54.0) 0.74 (0.39–1.42)
30 + kg/m2 17 (51.5) 16 (48.5) 0.88 (0.43–1.80) 16 (48.5) 17 (51.5) 0.42 (0.20–0.90)
HbA1c (mean, SD) 5.4 (0.4) 5.3(0.3) .05 0.49 (0.24–1.02) 5.4 (0.4) 5.3 (0.3) .03 0.64 (0.26–1.58)
Vitamin D (mean, SD) 49.5 (22.9) 51.1 (22.9) .15 1.01 (0.99–1.02) 51.3 (23.7) 50.9 (22.4) .83 1.01 (0.99–1.01)
Vitamin D groupc .09 .64
Deficiency 25 (53.2) 22 (46.8) 0.77 (0.40–1.45) 18 (37.5) 30 (62.5) 0.99 (0.47–2.11)
Insufficiency 95 (58.3) 68 (41.7) 0.62 (0.40–0.95) 73 (44.5) 91 (55.5) 0.80 (0.49–1.3)
Normal 87 (46.5) 100 (53.5) 1.0 (ref) 77 (41.0) 111 (59.0) 1.0 (ref)
Smoking .17 .71
Yes 50 (56.8) 38 (43.2) 0.7 (0.44–1.12) 37 (42.0) 51 (58.0) 0.82 (0.47–1.42)
No 164 (48.0) 178 (52.0) 1.0 (ref) 135 (39.1) 210 (60.9) 1.0 (ref)
Daily snuff use .03 .11
Yes 47 (40.9) 68 (59.1) 1.63 (1.06–2.51) 38 (33.0) 77 (67.0) 1.50 (0.88–2.56)
No 168 (53.0) 149 (47.0) 1.0 (ref) 135 (42.2) 185 (57.8) 1.0 (ref)
Alcohol use .03 .009
> 4 times/month 11 (57.9) 8 (42.1) 2.09 (0.62–7.05) 8 (42.1) 11 (57.9) 2.75 (0.77–9.86)
2–4 times/month 111 (48.9) 116 (51.1) 3.01 (1.29–6.99) 88 (38.8) 139 (61.2) 4.63 (1.95–11.04)
� 1 time/month 70 (45.2) 85 (54.8) 3.49 (1.47–8.28) 56 (35.4) 102 (64.6) 3.83 (1.59–9.22)
Never 23 (74.2) 8 (25.8) 1.0 (ref) 21 (67.7) 10 (32.3) 1.0 (ref)
Physical activityd .02 .05
Low level 21 (34.4) 40 (65.6) 2.35 (1.29–4.30) 20 (32.3) 42 (67.7) 1.83 (0.91–3.71)
Medium level 100 (55.2) 81 (44.8) 1.0 (ref) 84 (46.4) 97 (53.6) 1.0 (ref)
High level 92 (48.9) 96 (51.1) 1.29 (0.86–1.94) 68 (35.8) 122 (64.2) 1.87 (1.14–3.07)
Atopic eczema .007 .37
Yes 19 (32.8) 39 (67.2) 2.28 (1.27–4.09) 20 (33.9) 39 (66.1) 1.71 (0.82–3.56)
No 199 (52.6) 179 (47.4) 1.0 (ref) 156 (41.1) 224 (58.9) 1.0 (ref)
Antibiotic use past 3 months .36 .01
Yes 39 (55.7) 31 (44.3) 0.76 (0.45–1.27) 38 (54.3) 32 (45.7) 0.54 (0.30–0.98)
No 179 (48.9) 187 (51.1) 1.0 138 (37.4) 231 (62.6) 1.0 (ref)
Values are number of subjects (%) if not otherwise stated.
BMI = body mass index; SD = standard deviation; HbA1c, glycated haemoglobin.
a Chi-square test for categorical and t-tests for continuous variables.
b Univariable logistic regression analysis. OR = Odd ratio CI = 95% confidence intervals
c Serum 25-hydroxyvitamin D: Deficiency = < 25 nmol/l; Insufficiency = 25–50 nmol/l; Normal = >50 nmol/l.
d Recreational physical activity: Low level = reading, watching TV, or other sedentary activity; Medium level = walking, cycling, or other forms of exercise at least 4
hours a week; High level = participation in recreational sports, heavy outdoor activities with minimum duration of 4 hours a week, or participation in heavy training or
sports competitions regularly several times a week.
https://doi.org/10.1371/journal.pone.0218511.t001
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types. S. aureus nasal carriage was positively associated with self-reported doctor diagnosed
atopic eczema, low recreational physical activity, daily snuff use, and use of alcohol (all
p< 0.05). S. aureus throat carriage was associated with low recreational physical activity and
use of alcohol, while use of antibiotics the past three months was negatively associated with
throat carriage (all p< 0.05).
A higher proportion of women using combination HC were nasal carriers compared to
non-users, and there was a positive association with higher oestrogen dosage. Progestin-only
contraceptives were negatively associated with nasal carriage (p< 0.001) (Table 2). There was
no evidence for differences in prevalence of throat carriage across categories of HC use.
In a multivariable logistic regression model, users of high dosage estrogen HC had a 2.4
fold higher odds of S. aureus nasal carriage as compared with non-users (OR = 2.44; 95%
CI = 1.39–4.28, adjusted for age, BMI, smoking, snuff- and alcohol use, recreational physical
activity, HbA1c and 25-OH-vitamin D levels, atopic eczema and the use of antibiotics in the
past three months) (Table 3). Users of low dosage estrogen HC had an adjusted OR of 2.14
compared to non-users (95%CI = 1.17–3.91). Users of progestin-only contraceptives had an
adjusted OR of 0.29 (95%CI = 0.12–0.67) compared to users of combination contraceptives
(results not presented in tables). In the same model, higher odds of S. aureus nasal carriage
was also observed for atopic eczema (OR = 2.50; 95%CI = 1.28–4.89), low physical activity
(OR = 2.12; 95%CI = 1.06–4.23), use of alcohol once a month or less (OR = 3.81; 95%
CI = 1.42–10.23), and use of alcohol 2–4 times a month (OR = 3.48; 95%CI = 1.32–9.21).
Weak statistical evidence was found for a negative association with increasing HbA1c
(OR = 0.52; 95%CI = 0.23–1.20).
Multivariable logistic regression analysis of S. aureus throat carriage showed a trend
towards modestly higher odds for participants using high (OR = 2.06; 95%CI = 0.96–4.44),
and low dosage (OR = 1.79; 95%CI = 0.89–3.60), combination HC versus non-users, but
this finding could also be due to chance (Table 3). There was a statistically significant higher
odds of S. aureus throat carriage for the use of alcohol once a month or less (OR = 3.39; 95%
CI = 1.29–8.86), for alcohol use 2–4 times a month (OR = 3.85; 95%-CI = 1.49–9.95), and for
high level physical activity (OR = 1.83; 95%CI = 1.04–3.21).
Test for interaction was performed by including multiplicative terms of two and two pre-
dictors in the logistic regression model. In the analysis for throat carriage, four interactions
were detected. There was an interaction between atopic eczema and HbA1c (p = 0.01),
between antibiotic use and alcohol use (p = 0.02), between age and smoking status (p = 0.04)
and between smoking and HbA1c (p = 0.05). In the analysis for nasal carriage, there was an
Table 2. Prevalence of S. aureus nasal and throat carriage by group of hormonal contraceptive use. The Tromsø Study Fit Futures 2.














Non-user 113 (58.2) 81 (41.8) <.001 84 (42.4) 114 (57.6) .460
Combination with Low estrogenb 36 (44.4) 45 (55.6) 27 (34.6) 51 (65.4)
Combination with High estrogen c 44 (35.8) 79 (64.2) 47 (37.6) 78 (62.4)
Progestin-onlyd 25 (65.8) 13 (34.2) 18 (47.4) 20 (52.6)
a Chi-square test
b Combination contraceptive with ethinyl estradiol dosage less than or equal to 20μg. Mercilon, Yasminelle, Loette 28, Nuvaring.
c Combination contraceptive with ethinyl estradiol dosage greater than or equal to 30μg. Marvelon, Yasmin, Microgynon, Oralcon, Diane, Synfase, Evra
d Progestin-only contraceptives. Cerazette, Nexplanon, Depo-provera.
https://doi.org/10.1371/journal.pone.0218511.t002
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Table 3. Associations between hormonal contraceptive use and S. aureus nasal and throat carriage. Odd ratios






OR (95%CI) OR (95%CI)
Hormonal contraceptive use
Non-user 1.0 (ref) 1.0 (ref)
Progestin-onlyb 0.63 (0.27–1.45) 0.90 (0.37–2.19)
Combination with low estrogenc 2.14 (1.17–3.91) 1.79 (0.89–3.60)
Combination with high estrogend 2.44 (1.39–4.28) 2.06 (0.96–4.44)
Age continuous 1.15 (0.84–1.58) 0.93 (0.65–1.32)
BMI continuous 0.99 (0.94–1.05) 0.96 (0.90–1.02)
HbA1c continuous 0.52 (0.23–1.20) 0.72 (0.26–1.96)
Vitamin D continuous 1.00 (0.99–1.01) 0.99 (0.98–1.00)
Atopic eczema
Yes 2.50 (1.28–4.89) 1.49 (0.68–3.31)
No 1.0 (ref) 1.0 (ref)
Smoking
Yes 0.53 (0.30–0.95) 0.75 (0.39–1.47)
No 1.0 (ref) 1.0 (ref)
Daily snuff use
Yes 1.39 (0.82–2.37) 1.55 (0.82–2.94)
No 1.0 (ref) 1.0 (ref)
Alcohol use
More than 4 times a month 2.12 (0.50–8.94) 1.98 (0.45–8.72)
2–4 times a month 3.48 (1.32–9.21) 3.85 (1.49–9.95)
Once a month or less 3.81 (1.42–10.23) 3.39 (1.29–8.86)
Never 1.0 (ref) 1.0 (ref)
Recreational physical activitye
Low level 2.12 (1.06–4.23) 1.35 (0.62–2.93)
Medium level 1.0 (ref) 1.0 (ref)
High level 1.30 (0.80–2.11) 1.83 (1.04–3.21)
Antibiotic use past 3 months
Yes 0.88 (0.49–1.57) 0.63 (0.32–1.24)
No 1.0 (ref) 1.0 (ref)
BMI = body mass index; HbA1c, glycated haemoglobin.
a All variables in the table are mutually adjusted for
b Progestin-only = Cerazette, Nexplanon, Depo-provera.
c Combination contraceptive with ethinyl estradiol dosage less than or equal to 20μg. Mercilon, Yasminelle, Loette
28, Nuvaring.
d Combination contraceptive with ethinyl estradiol dosage greater than or equal to 30μg. Marvelon, Yasmin,
Microgynon, Oralcon, Diane, Synfase, Evra
e Recreational physical activity: Low level = reading, watching TV, or other sedentary activity; Medium
level = Walking, cycling, or other forms of exercise at least 4 hours a week; High level = Participation in recreational
sports, heavy outdoor activities with minimum duration of 4 hours a week, or participation in heavy training or
sports competitions regularly several times a week.
https://doi.org/10.1371/journal.pone.0218511.t003
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interaction between physical activity and HbA1c (p<0.00) and between use of antibiotics and
smoking status (p = 0.04). None of the interactions affected the main result and where there-
fore not included in the final analysis. We performed sensitivity analysis to check the robust-
ness of our results. The results presented in tables were generated from multivariable logistic
regression analysis in which observations with missing values were excluded. A multiple impu-
tation analysis was used to evaluate the effect of differently handled data analysis, but the esti-
mates were not significantly changed.
Discussion
This is the first report on the association between use of HC and S. aureus carriage based on a
representative sample of healthy women aged 17–21 years. We have demonstrated a strong
association between use of combination HC and nasal carriage, where the association is
strengthen with higher dosage of estrogen. Women using combination HC had more than
doubled odds for nasal carriage compared with non-users, suggesting that exogenous estrogen
is a major predictor of S. aureus nasal carriage. Among users of combination HC containing
both progestin and estrogen, the S. aureus nasal carriage prevalence was 64.2% (79/123) in the
high-estrogen group and 55.6% (45/81) in the low-estrogen group. This may suggest a dose-
response relationship. In contrast, users of progestin-only HC had an OR of 0.29 for nasal
carriage compared to women using combination therapy. This substantial difference in risk
between the HC-user groups suggests that estrogen and progestin have opposite immune-
modulatory effects on S. aureus colonization, and that the risk associated with exogenous
estrogen alone is considerably higher than that of combination HC.
Our findings are supported by three epidemiological studies in adults, one on endogenous
estrogen [21] and two on HC use [19–21]. Zanger et al did the first study of HC use in a
larger population of 694 women in Germany [19]. The doubled odds of S. aureus nasal car-
riage in our study lies between their observed 60% higher risk of S. aureus nasal carriage at
baseline and tripled risk of being persistent carrier after two months follow-up. These
authors took two nasal swabs at each time point, and defined only those with both samples
positive for S. aureus after direct culturing as carriers, while in the TTF2 we used one nasal
swab cultured with enrichment broth. This could explain some of the difference in risk esti-
mates between the studies. Also, there were differences in age, type of source population (vis-
itors to travel clinic versus students in upper-secondary school) and access to information on
possible confounding factors. The other study on HC use and S. aureus has limited validity
as the sample size was small [20]. Our study provides the first evidence for differences in the
effect of progestin-only and combination HC on S. aureus colonization, as hypothesised by
Zanger’s group, who were unable to explore this due to the low prevalence of progestin-only
users [19].
Nasal carriage of S. aureus is generally considered as a subclinical inflammatory process
due to suppression of the innate immune system [28]. Immune responses vary with gender
and the reproductive phase, suggesting that factors associated with reproduction regulate
immune response [29]. There have been conflicting results on the association between HC use
and immunoglobulin production [30–32]. One study showed decreased immunoglobulin lev-
els in HC users [32]. A recent study demonstrated an association between higher Toll-like
receptor 9 (TLR9) transcription levels and non-carrier status of S. aureus [33]. This study also
showed that both the association with TLR9 genotype and transcription level were modified
by sex, suggesting a role of reproductive hormones in S. aureus immunity. This may be under-
lying biological mechanisms that can explain why users of combination HC are more likely to
be nasal carriers of S. aureus.
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Though not statistically significant, our analysis shows a lower risk of S. aureus nasal car-
riage in progestin-only users compared to non-users, contrasting the higher risk among users
of combination HC. These differences point to direct exogenous hormonal effects, and that
the observed associations are not due to environmental factors such as differences in human
contact between non-user group and user group. Nevertheless, we cannot rule out that
unknown risk factors may account for some of the observed associations.
The study demonstrate a high overall prevalence in S. aureus carriage with a prevalence of
nasal carriage of 50% (218/436) and a prevalence for throat carriage of 60% (263/439). In a pre-
vious validation study (unpublished), the prevalence of enriched samples were 70% for throat
samples and 49% for nasal samples. When using direct cultivation of the swabs we detected a
prevalence of 36% for throat samples and 36% for nasal samples. The overall high prevalence
in our study is the result of the method used and must be taken in to consideration when com-
paring to other studies.
The main strengths in our study include a population-based design with high attendance
and thereby reduced risk of selection bias. Exogenous hormone exposure was assessed in
photo-assisted interviews by trained nurses to reduce the risk of information bias. Thus, we
may assume that the TFF2 data are representative for Norwegian adolescents and youth popu-
lations from similar modern societies. As TFF2 includes detailed information on lifestyle and
health, we were able to adjust for possible confounding. DAGitty 2.3 and Akaike Information
Criterion (AIC) were used for selecting the optimal regression model.
We included both smoking status and snuff use as covariates in the model as smoking has
been consistently associated with lower S. aureus nasal carriage in adults [1, 5–6]. Considering
that this is a healthy, young population the value of adjusting for HbA1c can be debated. Very
few subjects reported no alcohol use or use more than 4 times per month. The association
between alcohol use and carriage should therefore be interpreted with caution.
A weakness in our study is that only one sample from throat and nose was taken from each
participant. This renders it impossible to distinguish between persistent and intermittent carri-
ers and may represent a detection bias of unknown effect. Due to the enrichment step before
plating of the nasal and throat swab cultures, quantification of S. aureus growth was irrelevant.
Data on duration of HC use and thereby cumulative exogenous hormone exposure was
unavailable. Thus, we were unable to test for these possible dose-response relationships.
We did not find the same association between HC use and S. aureus carriage based on
throat samples as with nasal samples. This may represent a true difference in the host-microbe
relationship between throat and nose. However, there are some methodological concerns relat-
ing to the throat swabs in our study. A possible source of bias can be the more complicated
sampling method for throat swabs with lower compliance due to participant discomfort. Fur-
thermore, we chose to include throat samples without any bacterial growth on the agar plates
in our analysis. The enrichment broth promotes growth of staphylococci, while other members
of upper respiratory microbiota are inhibited by the relatively high concentration of sodium
chloride. Therefore, agar plates with no bacterial growth were included in the study as valid
negative throat samples. The pilot study showed that nasal swab samples cultured within 9
days after sampling gave the same culturing results on both control agar and S. aureus agar
plates as culturing on the day of sampling. We did not include throat swab samples in the pilot
study. However, we assume that for throat swabs S. aureus culture has similar validity as nasal
swabs, while growth on control agar has lower validity. All the potential sources of bias men-
tioned are sources of non-differential bias, as there is no obvious link to HC use.
In summary, we report novel evidence for an association between use of HC and risk of S.
aureus nasal carriage in female adolescents. Furthermore we observe that progestin-estrogen
combination users have higher risk while progestin-only users have lower risk of nasal carriage
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compared to non-users. Our data support that exogenous estrogen is a major risk factor with
potentially large impact on the S. aureus burden in the youth population. Our study has a bio-
logical foundation [33], demonstrates a dose response relationship, and the results are sup-
ported by data from another study including a different group of participants [19]. This study,
together with existing knowledge, provides evidence for a causal association between exoge-
nous estrogen exposure from hormonal contraceptives and nasal carriage of S. aureus. An
experimental study design is needed to establish the role of exogenous sex steroids in S. aureus
colonization in women.
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